The independent source for health policy research, polling, and news.
741 - 760 of 828 Results
As the nation awaits a vaccine to end the pandemic, local health departments say they lack the staff, money, tools ― and a unified plan ― to distribute, administer and track millions of vaccines, most of which will require two doses. Dozens of doctors, nurses and health officials interviewed by KHN and The Associated Press expressed their concern and frustration over federal shortcomings.
The nation’s top infectious disease official is confident that an independent panel will base vaccine approval on science, not politics.
Donald Trump accepted his party's nomination to seek reelection for a second term as president in front of a partisan audience that appeared to largely lack masks and opt against social distancing.
A robust sign-up for flu shots could help head off a nightmare scenario in the coming winter of hospitals stuffed with both COVID-19 patients and those suffering from severe effects of influenza. Plus, no one knows how flu and COVID might interact if a patient got both.
Harbor-UCLA Medical Center serves patients who are especially vulnerable to the coronavirus: They are essential workers, have chronic diseases and are members of underrepresented racial and ethnic groups. When the safety-net hospital kicks off enrollment for its COVID-19 vaccine trial Wednesday, it will look to those patients to participate.
Advocates of cheap and widely available vaccines thought the pandemic might change business as usual. They were wrong.
Polio terrified Americans, and in 1955, when Jonas Salk’s vaccine became available, they snapped it up like candy. Sixty-five years later, COVID is the latest dread virus, but many undercurrents could inhibit its acceptance.
A small allergy clinic in Medford, Oregon, might seem an unlikely place to recruit hundreds of volunteers to test the Moderna vaccine against COVID-19. But its steward has a record of leading hundreds of clinical trials.
People have flooded U.S. testing sites with requests to participate in the pivotal, late-stage clinical trials of the first two COVID-19 vaccine candidates.
Vaccines engineered to protect the public from influenza, hepatitis B, tetanus and rabies are less effective for obese people, leaving them more vulnerable to serious illness. As scientists race to develop a COVID-19 vaccine, experts say obesity could prove an impediment — a sobering prospect for a nation in which nearly half of all adults are obese.
Teams are starting to test vaccines using messenger RNA or chimpanzee cold viruses to inoculate humans. Will their benefits last?
President Donald Trump’s sobering view of COVID-19 didn’t last long – this week, he was back to pushing hydroxychloroquine, a drug that has been shown not to work in treating the virus. Meanwhile, Republicans on Capitol Hill are still scrambling to agree among themselves and with the White House on the next coronavirus relief bill, as both a moratorium on evictions and extra unemployment payments expire. And the debate over drug prices, which was going to be one of the biggest health issues of this election year, makes a brief appearance. Alice Miranda Ollstein of Politico, Mary Ellen McIntire of CQ Roll Call and Anna Edney of Bloomberg News join KHN’s Julie Rovner to discuss this and more. Also, Rovner interviews KHN’s Markian Hawryluk, who wrote the latest KHN-NPR “Bill of the Month” story about a surprise bill from a surprise surgical assistant.
The FDA must approve any coronavirus vaccine before it’s widely distributed, but political pressure could cloud the decision.
Under ordinary circumstances, these phases of vaccine development can take years to complete. But now, during the age of coronavirus, the timeline is being shortened. Here's an inventory of where things stand.
A federal study finds 35% of people 60 and older were vaccinated for shingles by 2018, up from 7% in 2008, but low-income people and those who are Black or Hispanic are far less likely to get vaccinated.
The United States is the only developed nation unable to balance cost, efficacy and social good in setting prices.
Easy-breezy guest writer Rachel Bluth fills you in on a healthy dose of news from this past week.
The Trump administration rolled back protections for transgender patients just days before the Supreme Court cemented LGBTQ rights under the Civil Rights Act. So, what now? Meanwhile, coronavirus politics reaches beyond health care settings. Anna Edney of Bloomberg News, Tami Luhby of CNN and Shefali Luthra of KHN join KHN’s Julie Rovner to discuss this and more. Also, for extra credit, the panelists recommend their favorite health stories of the week they think you should read, too.
KHN senior correspondent Jordan Rau spins through this week’s essential health care news.
KHN executive editor Damon Darlin wades through mounds of health care policy stories — so you don’t have to.
© 2026 KFF